23
Jan
2020
Much Ado about Coronavirus and 23andMe Hits the Wall
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $149 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account. 
Share:
16
Jan
2020
Lilly’s Half-Measure on Insulin, Illumina’s Up-Market Play, & the Little Deals from SF
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $149 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
Share:
13
Jan
2020
A New Cholesterol-Lowering Drug at a Low Price: Tim Mayleben on The Long Run
Today’s guest on The Long Run is Tim Mayleben. Tim is the CEO of Ann Arbor, Michigan-based Esperion Therapeutics. Esperion is bucking a few of the trends you’ve seen in biotech the past decade. It has developed a cholesterol-lowering drug, bempedoic acid. The drug is currently under review by regulators in the US and Europe. It is expected to be...Read More
Share:
12
Jan
2020
EQRx Taps Zeitgeist, Raises $200m For Innovative Drugs at Aggressive Low Prices
Alexis Borisy is smart. As in high IQ. But there’s more to biopharma than that. “As my grandmother used to say, ‘You can be smart, smart, smart…but dumb,’” Borisy said. Some old wisdom is part of what’s driving Cambridge, Mass.-based EQRx. The company, started by the former Third Rock Ventures partner and backed by $200 million of “smart money” in...Read More
Share:
9
Jan
2020
MRNA Vaccines Impress, Blueprint Wins First FDA OK, & Calif. Gov. Stares Down Biotech on the Eve of #JPM20
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $149 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
Share:
30
Dec
2019
Designer Proteins as Better Therapies: David Baker on The Long Run
Today’s guest on The Long Run is David Baker. David is a biochemistry professor at the University of Washington, a Howard Hughes Medical Institute investigator, and the director of The Institute for Protein Design at the University of Washington. Just like the name suggests, this institute works on designing proteins with special properties. Sometimes these proteins are designed on computers,...Read More
Share:
3
Dec
2019
Sticking With Epigenetics During Lean Times: Jigar Raythatha on The Long Run
Today’s guest on The Long Run is Jigar Raythatha. Jigar is the CEO of Cambridge, Mass.-based Constellation Pharmaceuticals. This company is built to develop drugs against epigenetic targets. Simply put, this is a way to turn genes on or off without altering the underlying DNA. The pharmaceutical industry fancied this idea about a decade ago, as a way to shut...Read More
Share:
2
Dec
2019
IFM, Staying Small, Raises (Merely) $55.5M, Promotes Former Novartis Exec to CEO
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $149 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
Share:
26
Nov
2019
Tamping Down Inflammation & Synaptic Dysfunction in Alzheimer’s: John Alam on The Long Run
Today’s guest on The Long Run is John Alam. John is the co-founder and CEO of Cambridge, Mass.-based EIP Pharma. This is a small company running clinical trials to test an unconventional idea for the treatment of Alzheimer’s. The gist is that if you can tamp down certain kinds of inflammation, you might be able to stop some of the...Read More
Share:
14
Nov
2019
Merck’s Ebola Vaccine Triumph, Weill’s $106M Neurohub & Teva’s Reversal
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $149 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
Share:
12
Nov
2019
Scientist, Entrepreneur, Rock Collector: Tim Springer on The Long Run
Today’s guest on The Long Run is Tim Springer. Tim wears many hats. First and foremost, he’s a scientist. An immunologist to be specific, at Harvard Medical School. He’s best known for his discovery of integrins, a class of transmembrane receptors. Now in his early 70s, Tim recently won the Gairdner Award, sometimes called the Canadian Nobel. The prize committee...Read More
Share:
7
Nov
2019
Takeda’s Busy Week, Halozyme’s Stumble, and New FDA Commish On Deck
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $149 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
Share:
31
Oct
2019
Amgen’s Bet on BeiGene, David Hung’s Megaround, & Zolgensma Speed Bump
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $149 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
Share:
29
Oct
2019
The Story of Henri Termeer: John Hawkins and Jim Geraghty on The Long Run
Today’s guests on The Long Run are John Hawkins and Jim Geraghty. John is a biotech industry veteran and the vice chairman of Odgers Berndtson, an executive recruiting firm in New York. He’s also the author of the new biography on Henri Termeer, the longtime CEO of Genzyme and one of the founding fathers of the biotech industry. Jim Geraghty...Read More
Share:
24
Oct
2019
Vertex’s Watershed for CF, Biogen’s Head-Scratcher, and Seattle Genetics Nails HER2Climb
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $149 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
Share:
17
Oct
2019
Reata Booms, Alexion Buys Achillion, & Teva Drops the Ball (Big Time)
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $149 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
Share:
15
Oct
2019
Turning Synthetic Biology Into ‘Living Drugs’: Synlogic’s Aoife Brennan on The Long Run
Today’s guest on The Long Run is Aoife Brennan. Aoife (it’s pronounced EE-fuh in her native Ireland) is the CEO of Synlogic Therapeutics. The company, based in Cambridge, Mass., is trying to build on years of work at MIT in synthetic biology. The basic idea is to create what the company calls Synthetic Biotics, or what you can call “Living...Read More
Share:
10
Oct
2019
UCB’s $2B Bet on Rare Disease, BioNTech’s IPO Haircut, & Greenwood Eases Out the Door
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $149 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
Share:
9
Oct
2019
12 VCs Who Matter, But You Hardly Ever Read About
This article was first published on November 20, 2017, then revised and updated October 9, 2019 Vinod Khosla, the tech venture capitalist, has said 95 percent of VCs add zero value to a startup other than cash. About four out of every five VCs, he said, actually damage their own investments with bad advice. When asked to apply the Khosla test...Read More
Share:
8
Oct
2019
Join Me and a Biotech Team on the Trek of a Lifetime for Cancer Research
Earlier this year, I led a team of 27 biotech professionals to Mt. Kilimanjaro, the highest peak in Africa. Each of us committed to raise $50,000 for cancer research at Fred Hutch. We ended up raising $1.6 million. We had an amazing time together. We all made it to the top. I want to do it again. This time we’re...Read More
Share: